Phenobarbital

Contraindicated

Phenobarbital Cabotegravir Apretude Decreased cabotegravir plasma concentrations with possible loss of virologic response Details Phenobarbital Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Phenobarbital Maraviroc Selzentry Decreased levels of maraviroc Details Phenobarbital Nifedipine Adalat® Reduced NIFEdipine exposure Details

Major

Phenobarbital Acetaminophen And Codeine Capital® & Codeine Explained Increased risk of CNS depression and reduced codeine exposure Details Phenobarbital Clindamycin ANTIROBE Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Omeprazole Gastrobim Explained Reduced omeprazole exposure, reduced efficacy of omeprazole, increased PHENobarbital exposure and an increased risk of PHENobarbit... Details Phenobarbital Amitriptyline Elavil Explained Reduced tricyclic antidepressant exposure and possible additive adverse effects Details Phenobarbital Sertraline Explained An increased risk of QT interval prolongation Details Phenobarbital Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, an increased risk of CNS depression, reduced buprenorphine exposure and reduced eff... Details Phenobarbital Colchicine Colcrys Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Simvastatin Flolipid Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Abemaciclib Verzenio Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Abrocitinib Cibinqo Explained Reduced abrocitinib exposure and reduced efficacy of abrocitinib Details Phenobarbital Acalabrutinib Calquence Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Amisulpride Injection Barhemsys An increased risk of QT interval prolongation Details Phenobarbital Apixaban Eliquis Explained Reduced apixaban exposure and an increased risk of thrombotic events Details Phenobarbital Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Phenobarbital Aripiprazole Injection Abilify An increased risk of QT interval prolongation, an increased risk of CNS depression, reduced ARIPiprazole exposure and reduced effi... Details Phenobarbital Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Phenobarbital Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation and an increased risk of CNS depression Details Phenobarbital Atogepant Qulipta Reduced atogepant exposure Details Phenobarbital Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Phenobarbital Avatrombopag Doptelet Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Azithromycin AzaSite An increased risk of QT interval prolongation Details Phenobarbital Belumosudil Rezurock Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Atorvastatin Atorvaliq Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Phenobarbital Abiraterone Abirtega Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Phenobarbital Alfuzosin UroXatral An increased risk of QT interval prolongation, reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Amlodipine Amvaz® Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Anagrelide Agrylin An increased risk of QT interval prolongation Details Phenobarbital Avanafil Stendra Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Axitinib Inlyta Reduced axitinib exposure Details Phenobarbital Bedaquiline Sirturo An increased risk of QT interval prolongation, reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Phenobarbital Bosutinib Bosulif Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Brigatinib Alunbrig Decreased brigatinib exposure and efficacy Details Phenobarbital Budesonide Entocort Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Phenobarbital Budesonide Nasal Spray Rhinocort Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details